Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and SBRT in advanced hepatocellular carcinoma
NCT03316872Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Feb 2018
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by University Health Network. Started Feb 2018; status: terminated.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03316872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316872.